Literature DB >> 2413074

Polyglutamation of methotrexate. Is methotrexate a prodrug?

B A Chabner, C J Allegra, G A Curt, N J Clendeninn, J Baram, S Koizumi, J C Drake, J Jolivet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2413074      PMCID： PMC423952          DOI： 10.1172/JCI112088

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  28 in total

1.  Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro.

Authors:  D W Fry; J C Yalowich; I D Goldman
Journal:  J Biol Chem       Date:  1982-02-25       Impact factor: 5.157

2.  Synthesis and retention of methotrexate polyglutamates by human small cell lung cancer.

Authors:  G A Curt; J Jolivet; B D Bailey; D N Carney; B A Chabner
Journal:  Biochem Pharmacol       Date:  1984-05-15       Impact factor: 5.858

3.  Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity.

Authors:  D W Fry; L A Anderson; M Borst; I D Goldman
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

Review 4.  Gene amplification in cultured animal cells.

Authors:  R T Schimke
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

5.  Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells with hydroxyurea.

Authors:  P C Brown; T D Tlsty; R T Schimke
Journal:  Mol Cell Biol       Date:  1983-06       Impact factor: 4.272

6.  Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells.

Authors:  J Jolivet; R L Schilsky; B D Bailey; J C Drake; B A Chabner
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

7.  Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.

Authors:  J Jolivet; B A Chabner
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

8.  Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture.

Authors:  E Frei; A Rosowsky; J E Wright; C A Cucchi; J A Lippke; T J Ervin; J Jolivet; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro.

Authors:  I Fabre; G Fabre; I D Goldman
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

10.  Folylpoly-gamma-glutamate synthesis by bacteria and mammalian cells.

Authors:  D J Cichowicz; S K Foo; B Shane
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396
View more
  99 in total

Review 1.  Molecular mechanism of methotrexate action in inflammation.

Authors:  B N Cronstein
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

Review 2.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

3.  Inhibition of neutrophil chemotaxis in methotrexate-treated rheumatoid arthritis patients.

Authors:  J W O'Callaghan; M J Forrest; P M Brooks
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

4.  Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.

Authors:  M J Ahern; S Kevat; W Hill; P J Hayball; H Harley; P D Hall
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

5.  A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression.

Authors:  Alexandra C Racanelli; Fiona B Turner; Lin-Ying Xie; Shirley M Taylor; Richard G Moran
Journal:  Mol Cell Biol       Date:  2007-11-12       Impact factor: 4.272

6.  The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor.

Authors:  Michele Visentin; Ersin Selcuk Unal; Rongbao Zhao; I David Goldman
Journal:  Cancer Chemother Pharmacol       Date:  2013-07-24       Impact factor: 3.333

Review 7.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Authors:  P Ranganathan; S Eisen; W M Yokoyama; H L McLeod
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

8.  Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats.

Authors:  Dong-Yang Liu; Hoi-Kei Lon; Yan-Lin Wang; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2013-04-07       Impact factor: 1.627

Review 9.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

10.  Characterisation of the bifunctional dihydrofolate synthase-folylpolyglutamate synthase from Plasmodium falciparum; a potential novel target for antimalarial antifolate inhibition.

Authors:  Ping Wang; Qi Wang; Yonghong Yang; James K Coward; Alexis Nzila; Paul F G Sims; John E Hyde
Journal:  Mol Biochem Parasitol       Date:  2010-03-27       Impact factor: 1.759
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.